The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
Giovanni FucàVincenzo GuariniCarlotta AntoniottiFederica MoranoRoberto MorettoSalvatore CoralloFederica MarmorinoSara LonardiLorenza RimassaAndrea Sartore-BianchiBeatrice BorelliMarco TampelliniSara BustreoMatteo ClaravezzaAlessandra BoccaccinoRoberto MurialdoAlberto ZaniboniGianluca TomaselloFotios LoupakisVincenzo AdamoGiuseppe ToniniEnrico CortesiFilippo de BraudChiara CremoliniFilippo PietrantonioPublished in: British journal of cancer (2020)
PIV is a strong predictor of survival outcomes with better performance than other well-known IIBs in patients with mCRC treated with first-line therapy. PIV should be prospectively validated to better stratify mCRC patients undergoing first-line therapy.